Product Reports Resources Pricing Login Book a demo

Curia

Biotech & Life Sciences · Albany, United States · Founded 1991 · IPO 1999

Formerly AMRI. Provides contract development and manufacturing services for pharmaceuticals, including drug substance, product, and fill-finish solutions

Valuation $1.74B
Revenue $1.18B
EBITDA $209M

Talent graph

Curia's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 5 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Curia's cap table

Sourced from Dealroom's funding history.

Series B+ 2 investors entered at this stage
Siena College
Rensselaer Polytechnic Institute

Global footprint

Where Curia has talent and traffic

Workforce by country
17 countries with
team presence
🇺🇸 United States48.9%
🇮🇳 India19.1%
🇪🇸 Spain11.2%
🇮🇹 Italy11.1%
🇬🇧 United Kingdom3.9%
Top 5 of 17 shown

Patent intelligence

$62M patent portfolio · 42 active families

Estimated portfolio value
$62M
3.6% of market cap · comparable to top peer Haisco ($74M)
42 active patent families
Where Curia innovates Combinatorial chemistryMedicinal chemistryArylBioinformaticsCancer research

Where Curia concentrates vs peers

Each axis is a top-10 topic across Curia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Curia's 9 investments and acquisitions.

Every disclosed deal where Curia appeared as a backer or acquirer, 2003–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

9 deals across Curia's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Curia deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Curia's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        9 of 9 deals

        Market sentiment

        What the market is saying about Curia

        An AI-synthesized read of the highest-engagement posts about Curia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Curia on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.